Abbott (ABT) Q2 2023: Base Business Organic Sales Jump 11.5% as Pipeline and Recovery Drive Momentum
Abbott’s core business delivered a broad-based acceleration, with double-digit organic growth across devices, pharma, and nutrition, offsetting COVID test declines. Margin recovery and a robust innovation pipeline underpin management’s confidence in sustained growth into 2024, despite ongoing FX and inflation headwinds. Investors should focus on the durability of new product launches and operational leverage as COVID testing recedes and the base business becomes the primary earnings driver.
Summary
- Base Business Acceleration: Double-digit organic growth across major segments signals broad demand recovery and pipeline execution.
- Margin Leverage Emerges: Operational efficiency and product mix shift support margin recovery even as inflation and FX persist.
- Pipeline-Driven Outlook: Abbott’s innovation cadence and market share gains position the company for continued top-line and margin expansion in 2024.
Business Overview
Abbott Laboratories is a diversified global healthcare company operating across four major segments: Medical Devices (including diabetes, cardiovascular, neuromodulation), Diagnostics (core lab, molecular, point-of-care), Established Pharmaceuticals (branded generics, primarily in emerging markets), and Nutrition (pediatric and adult nutritionals). The company generates revenue by selling medical products, diagnostic systems, branded pharmaceuticals, and nutritional products to hospitals, clinics, and consumers worldwide. COVID testing, previously a significant contributor, is now a diminishing part of the mix, with the underlying base business regaining prominence.
Performance Analysis
Abbott’s Q2 results reveal a decisive pivot back to core business strength, as organic sales excluding COVID testing grew 11.5% year-over-year. Medical Devices led the surge, up more than 14% organically, fueled by robust diabetes care (Libre, continuous glucose monitoring, +25%) and double-digit cardiovascular growth. Established Pharmaceuticals posted 12.5% growth, driven by strong execution in India and China and across key therapeutic areas. Nutrition rebounded sharply, with U.S. pediatric nutrition up over 20% as Abbott recovered approximately 75% of its lost infant formula market share post-recall. International nutrition grew 6%, led by both pediatric and adult segments.
Diagnostics, excluding COVID, grew 7% organically, anchored by 10% growth in Core Lab, reflecting a global return of routine testing and a steady recovery in blood transfusion diagnostics. COVID testing sales continued their expected decline, now forecast at $1.3 billion for the year (down from $1.5 billion), as public health emergency demand ebbs. Margin performance is stabilizing: adjusted gross margin was 55.4%, with inflation and FX still weighing, but operational leverage from prior investments and product mix improvements are supporting a return to pre-pandemic operating margin levels.
- Device Momentum: Diabetes and cardiovascular platforms outperformed, with Libre and new launches (Avere, TactiFlex, TriClip) driving share gains and pipeline visibility.
- Nutrition Recovery: U.S. pediatric nutrition’s rapid share recapture is restoring profitability and supply chain stability post-recall.
- Diagnostics Mix Shift: Routine testing and blood bank recovery offset COVID test volume declines, while Alinity placements and new assay development remain strategic levers.
Growth was geographically broad-based, with China reopening adding only about one point to overall growth, underscoring the strength of the global recovery. FX pressure persisted, negatively impacting reported sales by 2.5%. The company’s ability to drive top-line growth is translating into higher base business earnings, now expected to contribute $4.10 per share for the year, up $0.15 from January guidance.
Executive Commentary
"Growth in the underlying base business accelerated, driven by improving market conditions and contributions from both new products and legacy growth platforms. And our pipeline continues to be highly productive, which will sustain our strong growth profile in the future."
Robert Ford, Chairman and Chief Executive Officer
"We are, however, seeing lower gross margins on our COVID tests really due to the significant decline in volumes that we've seen compared to our assumptions at the beginning of the year. And I think for the balance of the year, we would expect to see gross margins roughly in the range of 56%. And then, you know, we would look for steady improvement after that."
Bob Funk, Executive Vice President, Finance and Chief Financial Officer
Strategic Positioning
1. Pipeline Productivity and Launch Cadence
Abbott’s innovation pipeline is delivering tangible growth, especially in Medical Devices. The launch of Avere dual-chamber leadless pacemaker, TactiFlex ablation catheter, and TriClip for tricuspid valve repair are expanding addressable markets and building long-term growth platforms. Libre’s expansion into basal coverage (France, U.S., Japan) and upcoming integration with pumps and dual-analyte sensors further entrench Abbott’s leadership in diabetes care.
2. Market Share Recovery in Nutrition
Rapid manufacturing ramp and brand strength are enabling Abbott to reclaim lost infant formula share, with the company targeting a full return to pre-recall share by year-end. This recovery is restoring both revenue and margin in a historically high-contribution segment, with Similac, infant formula brand, regaining leadership in key sub-segments.
3. Emerging Markets as a Growth Engine
Established Pharmaceuticals continues to outperform in emerging markets, leveraging a “local for local” strategy and regionalization to capture demographic and socioeconomic tailwinds in India, China, and beyond. This business is delivering sustained high single- to low double-digit growth, providing diversification and resilience against developed market volatility.
4. Diagnostics Platform Optimization
Abbott is balancing Core Lab instrument placements with margin discipline, focusing on expanding assay menus and leveraging installed base for higher-margin consumables. Blood bank recovery and point-of-care innovation (such as rapid concussion tests) are key growth vectors as COVID testing fades.
5. Operational Leverage and Cost Structure
Margin recovery is being driven by operational leverage from prior COVID-era investments, improved product mix, and ongoing cost management. Gross margin improvement is a stated priority, with input cost deflation and supply chain normalization expected to provide incremental upside into 2024.
Key Considerations
This quarter marks a strategic inflection as Abbott’s base business becomes the primary earnings engine, with COVID testing now a minor contributor. Investors should weigh the following:
Key Considerations:
- Product Launch Execution: Sustained outperformance in devices and diagnostics hinges on successful commercialization and adoption of new platforms like Libre 3, Avere, and TriClip.
- Nutrition Share Recovery: Full restoration of U.S. infant formula share is critical for margin and volume normalization, with manufacturing ramp as a key variable.
- Margin Expansion Potential: Ongoing cost pressures are being mitigated by mix shift and operational leverage, but further improvement depends on commodity and FX trends.
- Emerging Market Resilience: Execution in India, China, and other emerging markets is a vital offset to developed market cyclicality.
- Diagnostics Menu Expansion: Adding new assays to the Alinity platform is essential for maximizing installed base economics and margin lift.
Risks
Key risks include persistent FX and inflationary headwinds, which continue to impact gross margin and reported sales. COVID testing volume declines remain a drag, though now largely anticipated. Execution risk around new product launches and nutrition share recovery is nontrivial, especially as Abbott targets a full return to pre-recall market share by year-end. Competitive pressure in diabetes care (CGM) and cardiovascular devices could temper growth if pipeline execution falters.
Forward Outlook
For Q3, Abbott guided to:
- Adjusted EPS of approximately $1.10
- Low double-digit organic sales growth in the base business (excluding COVID testing)
For full-year 2023, management maintained guidance:
- Adjusted EPS of $4.30 to $4.50
- COVID testing sales forecast lowered to $1.3 billion
Management highlighted several factors that will drive results:
- Continued broad-based demand recovery across institutional and consumer-facing businesses
- Pipeline productivity and new product launches as key growth drivers
Takeaways
Abbott’s Q2 results confirm a decisive return to organic growth, with the base business now the clear engine of value creation. Margin recovery and pipeline momentum provide a credible path for sustained performance into 2024.
- Productivity Engine: New device launches and market share recovery in nutrition are restoring growth and profitability, even as COVID fades.
- Operational Leverage: Prior investments and disciplined cost control are supporting margin expansion and mitigating inflation/FX headwinds.
- Pipeline Watch: Investors should monitor the cadence of new launches and the pace of nutrition share recovery as key drivers of upside or risk.
Conclusion
Abbott’s Q2 marks a strategic transition, with the base business firmly in the driver’s seat and pipeline execution delivering broad-based growth. Margin recovery and innovation momentum position the company well for the second half and into 2024, barring unforeseen macro shocks or execution missteps.
Industry Read-Through
Abbott’s performance provides a strong read-through for global medtech and diagnostics peers: Resilient demand for medical devices, diagnostics, and branded generics is returning as health systems normalize post-pandemic. Innovation cadence and local-for-local strategies are proving critical in emerging markets, while margin recovery is increasingly tied to pipeline execution and operational leverage rather than pure volume recovery. COVID testing’s fade is now a sector-wide reality, and future winners will be those with diversified portfolios, robust pipelines, and disciplined cost management. Competitors in diabetes technology, cardiovascular, and diagnostics should note the accelerating pace of new product launches and the strategic importance of menu expansion and installed base monetization.